Advanced Enzyme Tech quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	190	186	+2.1%
EBITDA	51.0	56.4	−9.7%
EBITDA margin	26.9%	30.4%	−3.5 pts
Profit before tax	53.5	54.9	−2.5%
Net profit	38.6	40.4	−4.6%
EPS	₹3.31	₹3.57	−7.3%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	190	203	172	185	186	167	169	146	155	158	161	158	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	13.0	7.2	8.5	10.3	8.9	8.7	7.7	9.6	7.0	9.5	14.4	6.1
	203	211	180	195	195	176	177	156	162	167	175	164
	54.5	56.0	45.6	48.7	44.0	45.9	36.8	39.1	40.2	35.9	44.0	29.9
	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	−4.8	1.0	−4.2	−4.2	6.1	0.1	2.1	−6.4	−6.0	−0.4	−8.9	7.1
	44.6	41.9	41.3	39.4	39.7	36.8	34.5	35.5	34.7	32.5	32.1	31.7
	0.6	0.6	0.6	0.7	0.8	0.8	0.9	0.9	0.9	0.8	0.7	0.8
	9.9	10.2	10.2	10.1	9.6	10.1	9.0	8.9	8.6	9.3	8.6	8.7
	44.6	41.3	39.9	40.5	39.7	38.7	40.5	35.5	34.5	34.5	40.0	37.8
	149	151	133	135	140	132	124	114	113	113	116	116
	51.0	63.2	49.4	60.1	56.4	45.6	55.3	42.4	51.2	55.4	53.8	51.3
	41.1	53.0	39.1	50.0	46.8	35.5	46.3	33.5	42.6	46.1	45.2	42.6
Profit
	53.5	59.7	47.0	59.5	54.9	43.5	53.0	42.2	48.7	54.7	58.9	47.9
	0.0	0.1	11.2	0.0	0.0	0.0	0.0	0.0	0.0	−15.1	0.0	0.0
	53.5	59.8	58.3	59.5	54.9	43.5	53.0	42.2	48.7	39.6	58.9	47.9
	15.1	13.3	11.9	15.7	15.5	14.1	13.8	8.7	12.9	13.1	17.0	13.5
	−0.1	1.2	3.2	−0.9	−1.0	2.6	0.3	0.1	0.8	−3.4	−0.6	−0.8
	14.9	14.6	15.1	14.8	14.5	16.7	14.1	8.8	13.7	9.7	16.4	12.7
	38.6	45.3	43.2	44.7	40.4	26.7	38.9	33.4	35.0	29.9	42.5	35.2
	38.6	45.3	43.2	44.7	40.4	26.7	38.9	33.4	35.0	29.9	42.5	35.2
	−1.4	47.9	11.9	31.2	3.8	0.7	13.1	4.9	0.2	1.0	2.9	7.3
	37.2	93.2	55.1	75.9	44.2	27.4	52.0	38.3	35.2	30.9	45.4	42.5
	37.1	43.0	42.5	43.3	39.9	26.5	37.6	32.8	34.2	28.3	41.8	34.4
	1.5	2.3	0.7	1.4	0.5	0.2	1.2	0.6	0.8	1.6	0.7	0.8
Per share
	₹3.31	₹3.84	₹3.80	₹3.87	₹3.57	₹2.37	₹3.36	₹2.94	₹3.05	₹2.53	₹3.74	₹3.08
	₹3.31	₹3.84	₹3.79	₹3.87	₹3.57	₹2.37	₹3.36	₹2.93	₹3.05	₹2.53	₹3.74	₹3.08
Other comprehensive income — detail
	−1.4	47.9	11.9	31.2	3.8	0.7	—	—	—	—	—	—
	0.0	0.6	0.7	0.1	−0.1	−0.4	−0.1	−0.2	−0.0	−0.1	−0.0	−0.0
	0.0	0.2	0.2	0.0	−0.0	−0.1	—	—	—	—	—	—
	—	—	—	—	—	—	−0.0	−0.1	−0.0	−0.0	−0.0	−0.0
	−1.4	47.5	11.4	31.1	3.8	1.0	13.1	5.0	0.2	1.1	3.0	7.3
	35.7	90.9	54.4	74.5	43.7	27.1	50.7	37.7	34.3	29.4	44.7	41.7
	1.5	2.3	0.7	1.4	0.5	0.3	1.2	0.5	0.8	1.6	0.7	0.8
Per share — as-filed variants
	₹3.31	₹3.84	₹3.80	₹3.87	₹3.57	₹2.37	₹3.36	₹2.94	₹3.05	₹2.53	₹3.74	₹3.08
	₹3.31	₹3.84	₹3.79	₹3.87	₹3.57	₹2.37	₹3.36	₹2.93	₹3.05	₹2.53	₹3.74	₹3.08
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	140	146	131	140	136	121	130	113	120	122	126	121
	73.8%	72.0%	75.9%	75.8%	73.1%	72.4%	77.0%	77.6%	77.8%	77.5%	78.2%	76.6%
Adjusted (ex-exceptional items) — derived
	53.5	59.7	47.0	59.5	54.9	43.5	53.0	42.2	48.7	54.7	58.9	47.9
	0.0	0.1	11.2	0.0	0.0	0.0	0.0	0.0	0.0	−15.1	0.0	0.0
	38.6	45.2	34.9	44.7	40.4	26.7	38.9	33.4	35.0	41.3	42.5	35.2
	₹3.31	₹3.83	₹3.07	₹3.87	₹3.57	₹2.37	₹3.36	₹2.94	₹3.05	₹3.50	₹3.74	₹3.08

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ADVENZYMES₹264.15

Advanced Enzyme Tech Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersAARTIPHARM AARTIDRUGS AGARWALEYE AKUMS ALIVUS APLLTD CORONA HCGMcap ₹2,956 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	157.8	160.9	157.8	154.5	146.1	169.1	167.2	185.9	184.5	171.9	203.4	189.8
Other Income	6.1	14.4	9.5	7.0	9.6	7.7	8.7	8.9	10.3	8.5	7.2	13.0
Total Income	163.9	175.3	167.3	161.5	155.7	176.8	175.9	194.8	194.8	180.4	210.6	202.8
Expenses
+ Cost of Materials Consumed	29.9	44.0	35.9	40.2	39.1	36.8	45.9	44.0	48.7	45.6	56.0	54.5
+ Purchases of Stock-in-Trade	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
+ Changes in Inventories	7.1	-8.9	-0.4	-6.0	-6.4	2.1	0.1	6.1	-4.2	-4.2	1.0	-4.8
+ Employee Benefit Expense	31.7	32.1	32.5	34.7	35.5	34.5	36.8	39.7	39.4	41.3	41.9	44.6
+ Finance Costs	0.8	0.7	0.8	0.9	0.9	0.9	0.8	0.8	0.7	0.6	0.6	0.6
+ Depreciation & Amortisation	8.7	8.6	9.3	8.6	8.9	9.0	10.1	9.6	10.1	10.2	10.2	9.9
+ Other Expenses	37.8	40.0	34.5	34.5	35.5	40.5	38.7	39.7	40.5	39.9	41.3	44.6
Total Expenses	116.0	116.5	112.6	112.8	113.5	123.8	132.5	139.9	135.3	133.4	150.9	149.3
EBITDA	51.3	53.8	55.4	51.2	42.4	55.3	45.6	56.4	60.1	49.4	63.2	51.0
EBIT	42.6	45.2	46.1	42.6	33.5	46.3	35.5	46.8	50.0	39.1	53.0	41.1
Profit
PBT before Exceptional Items	47.9	58.9	54.7	48.7	42.2	53.0	43.5	54.9	59.5	47.0	59.7	53.5
+ Exceptional Items	0.0	0.0	-15.1	0.0	0.0	0.0	0.0	0.0	0.0	11.2	0.1	0.0
Pretax Income	47.9	58.9	39.6	48.7	42.2	53.0	43.5	54.9	59.5	58.3	59.8	53.5
+ Current Tax	13.5	17.0	13.1	12.9	8.7	13.8	14.1	15.5	15.7	11.9	13.3	15.1
+ Deferred Tax	-0.8	-0.6	-3.4	0.8	0.1	0.3	2.6	-1.0	-0.9	3.2	1.2	-0.1
Tax Expense	12.7	16.4	9.7	13.7	8.8	14.1	16.7	14.5	14.8	15.1	14.6	14.9
Net Income	35.2	42.5	29.9	35.0	33.4	38.9	26.7	40.4	44.7	43.2	45.3	38.6
+ Net Income — Continuing Ops	35.2	42.5	29.9	35.0	33.4	38.9	26.7	40.4	44.7	43.2	45.3	38.6
+ Other Comprehensive Income	7.3	2.9	1.0	0.2	4.9	13.1	0.7	3.8	31.2	11.9	47.9	-1.4
Total Comprehensive Income	42.5	45.4	30.9	35.2	38.3	52.0	27.4	44.2	75.9	55.1	93.2	37.2
Net Income to Common	34.4	41.8	28.3	34.2	32.8	37.6	26.5	39.9	43.3	42.5	43.0	37.1
Minority Interest	0.8	0.7	1.6	0.8	0.6	1.2	0.2	0.5	1.4	0.7	2.3	1.5
Per Share
Basic EPS	3.08	3.74	2.53	3.05	2.94	3.36	2.37	3.57	3.87	3.80	3.84	3.31
Diluted EPS	3.08	3.74	2.53	3.05	2.93	3.36	2.37	3.57	3.87	3.79	3.84	3.31
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	0.7	3.8	31.2	11.9	47.9	-1.4
+ Items NOT to be Reclassified to P&L	-0.0	-0.0	-0.1	-0.0	-0.2	-0.1	-0.4	-0.1	0.1	0.7	0.6	0.0
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	-0.1	-0.0	0.0	0.2	0.2	0.0
+ Tax on Items NOT to be Reclassified — alt tag	-0.0	-0.0	-0.0	-0.0	-0.1	-0.0	—	—	—	—	—	—
+ Items to be Reclassified to P&L	7.3	3.0	1.1	0.2	5.0	13.1	1.0	3.8	31.1	11.4	47.5	-1.4
Comprehensive Income — Owners of Parent	41.7	44.7	29.4	34.3	37.7	50.7	27.1	43.7	74.5	54.4	90.9	35.7
Comprehensive Income — Non-controlling Interests	0.8	0.7	1.6	0.8	0.5	1.2	0.3	0.5	1.4	0.7	2.3	1.5
Per Share — as-filed variants
Basic EPS — Continuing Operations	3.08	3.74	2.53	3.05	2.94	3.36	2.37	3.57	3.87	3.80	3.84	3.31
Diluted EPS — Continuing Operations	3.08	3.74	2.53	3.05	2.93	3.36	2.37	3.57	3.87	3.79	3.84	3.31
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	120.8	125.9	122.3	120.3	113.4	130.3	121.1	135.9	140.0	130.5	146.4	140.1
Gross Margin %	76.56	78.21	77.49	77.84	77.62	77.04	72.43	73.08	75.85	75.92	72.01	73.82
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	47.9	58.9	54.7	48.7	42.2	53.0	43.5	54.9	59.5	47.0	59.7	53.5
− Exceptional Items (reconciliation)	0.0	0.0	-15.1	0.0	0.0	0.0	0.0	0.0	0.0	11.2	0.1	0.0
Net Income Adj (tax-effected)	35.2	42.5	41.3	35.0	33.4	38.9	26.7	40.4	44.7	34.9	45.2	38.6
EPS Adj	3.08	3.74	3.50	3.05	2.94	3.36	2.37	3.57	3.87	3.07	3.83	3.31
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Filed Debt Equity	0.00	—	0.00	0.00	0.00	—	0.02	0.02	0.01	0.01	0.01	0.01
Filed Dscr	—	—	—	5.00	—	—	5.54	6.96	8.62	9.68	9.27	8.23
Filed Iscr	—	—	—	—	—	—	41.43	60.65	68.74	67.91	90.83	70.05
Paid Up Equity Capital	22.4	22.4	22.4	22.4	22.4	22.4	22.4	22.4	22.4	22.4	22.4	22.4

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Advanced Enzyme Tech Q2 FY27 results date

Advanced Enzyme Tech (NSE: ADVENZYMES) will announce its Q2 FY27 results (July–September 2026) on Saturday, 31 October 2026, according to the board-meeting notice it filed on 23 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit attributable to shareholders was ₹37.1 crore, down 7.1% from ₹39.9 crore in Q1 FY26 and down 13.7% from ₹43 crore in Q4 FY26. Revenue from operations was ₹190 crore, up 2.1% year on year and down 6.7% from the previous quarter.

Board-meeting notice filed: 23 October 2026
Q2 FY26 results (a year earlier): 12 November 2025
Q1 FY27 results (the latest): 8 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 31 October 2026Saturday · notice filed 23 Oct
Q1 FY27 net profit: ₹37.1 Cr−7.1% vs Q1 FY26−13.7% vs Q4 FY26
Q1 FY27 revenue: ₹190 Cr+2.1% vs Q1 FY26−6.7% vs Q4 FY26
Q1 FY27 operating margin: 21.6%−3.5 pts vs Q1 FY26−4.4 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹43.3 CrRevenue ₹185 Cr
Q1 FY27 EPS (basic): ₹3.31

Questions

When will Advanced Enzyme Tech announce its Q2 FY27 results?

On 31 October 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 23 October 2026). Last year it reported Q2 FY26 on 12 November 2025.

What will Advanced Enzyme Tech's Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit attributable to shareholders was ₹43.3 crore and revenue from operations ₹185 crore. The latest quarter, Q1 FY27, had a net profit of ₹37.1 crore and revenue of ₹190 crore.

What was Advanced Enzyme Tech's revenue in FY26?

Revenue from operations was ₹746 crore in FY26 (April 2025–March 2026), up 17.1% from ₹637 crore in FY25. It was ₹624 crore in FY24 and ₹541 crore in FY23: up 37.9% over three years, 11.3% a year on average.

What were Advanced Enzyme Tech's Q1 FY27 results?

Consolidated net profit attributable to shareholders was ₹37.1 crore, down 7.1% from ₹39.9 crore in Q1 FY26 and down 13.7% from ₹43 crore in Q4 FY26. Revenue from operations was ₹190 crore, up 2.1% year on year and down 6.7% from the previous quarter.

How has Advanced Enzyme Tech's profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: ₹43.3 crore in Q2 FY26, ₹42.5 crore in Q3 FY26, ₹43 crore in Q4 FY26 and ₹37.1 crore in Q1 FY27. That is ₹166 crore over the four quarters, up 21.2% from ₹137 crore in the four quarters before. Revenue from operations: ₹185 crore, ₹172 crore, ₹203 crore and ₹190 crore.

What was Advanced Enzyme Tech's net profit in FY26?

Consolidated net profit attributable to shareholders was ₹169 crore in FY26 (April 2025–March 2026), up 28.7% from ₹131 crore in FY25. It was ₹133 crore in FY24 and ₹106 crore in FY23: up 59.7% over three years, 16.9% a year on average.

Where do these Advanced Enzyme Tech figures come from?

From Advanced Enzyme Tech's own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.